Paclitaxel-eluting balloon versus everolimus-eluting stent in patients with diabetes mellitus and in-stent restenosis: Insights from the randomized DARE trial.
Bimmer E P M ClaessenJosé P S HenriquesJeroen VendrikKirsten Boerlage-van DijkRené J van der SchaafMartijn MeuwissenNiels van RoyenA T Marcel GosselinkMarleen H van WelyAtilla DirkaliE Karin ArkenboutJan J PiekJan BaanPublished in: Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions (2018)
In patients with ISR and DM, use of a PEB resulted in similar 6-months in-segment minimal lumen diameter and comparable rates of MAE. In-segment late loss at 6 months was significantly lower in the PEB arm. Although larger trials in DM patients with ISR are necessary, PEB is a promising treatment option obviating the need for additional stent implantation.